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Hypertension, a common feature in chronic kidney disease (CKD), is an independent risk factor for CKD progression and
cardiovascular disease. Although inhibitors of the renin-angiotensin system (RAS) exert salutary effects on blood pressure control
and proteinuria in CKD patients, their activity towards traditional and novel oxidative markers is largely unknown. We studied
the effects of 6-month treatment with telmisartan versus a combination of telmisartan and ramipril on plasma concentrations
of low molecular mass (LMW, including homocysteine and cysteine) and protein thiols (PSH) plasma concentration and their
relationships with carotid intima media thickness (IMT), in 24 hypertensive CKD patients (age 60 ± 12 years, 8 females and 16
males). Pretreatment PSH concentrations were independently associated with IMT (𝑟 = −0.42, 𝑝 = 0.039). Neither treatment
affected plasma LMW thiols, in both reduced and total form. By contrast, both treatments increased PSH plasma concentrations
and reduced IMT, although significant differences were only observed in the combined treatment group. Our results suggest that
the beneficial effects of combined RAS inhibitor treatment on IMT in hypertensive CKD patients may be mediated by a reduction
of oxidative stress markers, particularly PSH.
1. Introduction
Hypertension is present in more than 80% of patients with
chronic kidney disease (CKD) and contributes to progression
towards end stage renal disease (ESRD) aswell as an increased
risk of cardiovascular events such as myocardial infarction
and stroke [1], leading to non-CKD-related causes of death
in this group. Moreover, there is good evidence that the
presence of hypertension inCKD is associatedwith structural
alterations of the arterial wall, in particular an increased
thickness of the intima media layers [2]. Carotid IMT has
been shown to independently predict adverse clinical out-
comes in CKD [3]. Although a prolonged increase in blood
pressure might be directly responsible for the development
and the progression of IMT [4], other factors are likely to be
involved. For example, a recent study has identified the role of
oxidative stress in the development of carotid IMT in young
CKD [5]. Evidence from a large number of clinical trials has
clearly demonstrated that adequate blood pressure control is
key to preventing adverse outcomes in CKD [6]. Inhibitors
of the renin-angiotensin system (RAS), such as angiotensin
converting enzyme inhibitors (ACEIs) and angiotensin II
receptor blockers (ARBs), have been found to slow the
progression of CKD to ESRD [7, 8]. Recent studies have also
compared the effects of different RAS inhibitors. For example,
in the ONTARGET study the ARB telmisartan had similar
cardiovascular and renal protective effects to the ACEI
ramipril in patients at high cardiovascular risk but was better
tolerated [9]. Despite the established beneficial effects of RAS
inhibitors in reducing proteinuria and in slowing the rate of
CKD progression, direct mechanistic comparisons between
ARBs and ACEIs, including possible effects on carotid IMT,
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have been poorly addressed. Although recent reports support
the hypothesis that RAS inhibition by either ramipril or
telmisartan suppresses inflammatory and lipid peroxidation
markers in nonhypertensive diabetic patients [10], there is
little information about other importantmarkers of oxidation
and cardiovascular risk such as LMW thiols, for example,
homocysteine (Hcy) or cysteine (Cys), and their redox status
modification during therapy. The highly reactive sulphur-
containing amino acid Hcy has long been shown to exert
detrimental effects on vascular homeostasis by inhibiting
nitric oxide synthesis and promoting oxidative stress and
inflammation [11]. Several studies have shown that higher
plasma/serum homocysteine concentrations independently
predict adverse cardiovascular outcomes [12]. Similar results
have also been reported for cysteine [13, 14]. In CKD patients
both Hcy and Cys plasma concentrations are commonly
increased thus contributing, at least in part, to the high
cardiovascular risk in this group [15]. Plasma LMW thiols
also include cysteinylglycine (CysGly), glutathione (GSH),
and glutamylcysteine (Glucys). These LMW thiols interact
via redox disulfide exchange reactions and reduced, free-
oxidized, and protein-bound forms of these species form a
dynamic system referred to as thiols redox status that also
comprises the free –SH groups of proteins (PSH) [16]. Since
CKD patients are normally characterized by an increased
oxidative stress and RAS inhibitors are reported to be able
to reduce oxidative markers in diabetic mice [17], evaluation
of total –SH groups in plasma may provide a more com-
prehensive assessment of the possible beneficial effects of
RAS inhibition on oxidative status as well as carotid IMT.
Thus, the aim of our study was to assess and compare the
effects of 6-month treatment with telmisartan (80mg day),
a relatively new ARB with better tolerability, and relatively
long duration of action in virtue of its longer half-life, versus
a combination of telmisartan and ramipril (40/5mg day) on
LMW and PSH plasma concentrations and carotid IMT in
patients with CKD. The objective was to evaluate whether
the salutary effects of telmisartan on the outcomes of interest
were augmented when combined with ramipril.
2. Methods
2.1. Subjects. Recruitment was performed as previously
described [15]. In brief, 24 CKD hypertensive patients (age
60 ± 12 years, 8 females and 16 males) were identified at the
Istituto di Patologia Medica, Azienda Ospedaliero Univer-
sitaria, with the following inclusion criteria: age > 18 years,
blood pressure ≥ 140/90mmHg, plasma LDL-cholesterol
concentrations > 100mg/dL (without concomitant hypolipi-
demic drugs), and presence of proteinuric CKD defined as
creatinine clearance > 20mL/min/1.73m2 combined with
urinary protein excretion rate > 0.3 g/24 h, without evidence
of urinary tract infection or overt heart failure (New York
Heart Association class III or more). Patients were of CKD
stage 3 or 4, not receiving dialysis. None of the selected
patients took any antihypertensive medications before the
enrollment. Exclusion criteria were previous or concomitant
treatment with steroids, anti-inflammatory and immunosup-
pressive agents, vitamin B6, vitamin B12, folate, or statin
and evidence or clinical suspicion of renovascular disease,
obstructive uropathy, type 1 diabetes, and vasculitis.
Enrolled patients were randomized to receive 6-month
treatment with telmisartan (80mg/day) versus a combination
of telmisartan and ramipril (40/5mg/day). Patients were
assessed at baseline and at the end of treatment. Informed
consent was obtained from each patient. The study was
approved by our institution ethics committee and complied
with the principles of the Helsinki Declaration.
2.2. Biochemical Analysis. Reduced and total LMW thiols
were determined by capillary electrophoresis LIF detection
as previously described [16, 18]. The LMW thiol redox status
was calculated by measuring the ratio of the sum of reduced
(r) and total (t) forms of thiols as follows: (rCysGly + rCys +
rHcy + rGSH + rGluCys)/(tCysGly + tCys + tHcy + tGSH +
tGluCys).
Plasma protein SH (PSH) determination was performed
by spectrophotometry with 5,5󸀠-dithiobis-2-nitrobenzoic
acid (DTNB) as titrating agent by measuring the absorbance
of conjugate at 405 nm [19]. Concentration in samples was
determined from a GSH standard curve. Proteins –SH con-
centrations were normalized versus protein plasma quantity
measured by Lowry’s method.
2.3. Blood Pressure Measurement. Blood pressure (BP) was
measured at the Istituto di Patologia Medica, Azienda
Ospedaliero Universitaria, by a trained research assistant
using a calibrated and validated digital sphygmomanometer.
BP measurements were taken with the patient in a seated
position with the arm supported at heart level, after a 5 min
rest and after abstaining from food, beverages containing caf-
feine, and smoking for at least 2 h prior to BP measurement.
BP was recorded as three serial measurements at intervals of
30 sec on both arms. The mean of the six BP readings was
used in the analysis. If a BP reading deviated by more than
10mmHg from the average reading, the BP measurement on
that arm was repeated.
2.4. Carotid IMT Measurement. The carotid artery was
scanned by two trained and certified sonographers blinded
to clinical information and treatment. All study subjects
were examined in the supine position with the head tilted
backward. Dedicated QIMT-Esaote software was used to
measure the left and right IMT of the posterior wall of
the common carotid, 1 cm distal to the bulb bifurcation, by
ultrasound 2D exam. The IMT assessment was performed
according to the recommendations of the Italian Society
of Vascular Diagnostics [20] and the standardized criteria
described by Mannheim Carotid Intima Media Thickness
Consensus to ensure full reliability [21]. The manual image
acquisition of carotid vessels was obtained before the auto-
matic measurement of IMT using QIMT (Quality Intima
Media Thickness) software, integrated into the instrument
(Esaote MyLab 30 gold), and QIMT software, using the RF
(Radio Frequency Data Processing). Two readings from both
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Table 1: Demographic and clinical characteristics of CKD randomized groups.
CKD (𝑛 = 24)
Group 1 (𝑛 = 12)
Telmisartan/ramipril
40/5mg/day
Group 2 (𝑛 = 12)
Telmisartan
80mg/day
Mean ± SD
or median
(IQR)
Mean ± SD
or median (IQR)
Mean ± SD
or median (IQR)
Sex, F/M (% F) 8/16 (33%) 4/8 (33%) 4/8 (33%)
Age, years 60 ± 12 62 ± 12 58 ± 13
Systolic BP, mmHg 133 ± 13 132 ± 13 133 ± 14
Diastolic BP, mmHg 80 ± 9 82 ± 8 77 ± 9
Creatinine, mg/dL 1.6 (1.1–2.1) 1.6 (1.0–2.3) 1.7 (1.3–2.0)
GFR, mL/min per 1.73m2 48 (32–66) 48 (22–71) 48 (34–66)
Proteinuria, g/24 h 0.95 (0.30–2.35) 0.52 (0.28–2.49) 1.28 (0.36–2.35)
IMT, mm 0.90 (0.73–1.00) 0.95 (0.72–1.05) 0.88 (0.73–1.00)
Total LMW thiols
t-CysGly, 𝜇mol/L 30.2 ± 8.6 31.6 ± 8.8 28.8 ± 8.4
t-Hcy, 𝜇mol/L 17.0 (12.1–24.4) 16.3 (12.1–26.3) 19.2 (11.8–23.7)
t-Cys, 𝜇mol/L 381 ± 98 391 ± 89 370 ± 109
t-GSH, 𝜇mol/L 7.5 ± 2.6 7.4 ± 2.1 7.6 ± 3.2
t-GluCys, 𝜇mol/L 5.8 (3.9–6.5) 5.7 (4.5–6.0) 5.4 (3.5–7.6)
Sum of total LMW thiols, 𝜇mol/L 444 ± 112 458 ± 106 432 ± 122
Reduced LMW thiols
r-Cys-Gly, 𝜇mol/L 6.2 ± 2.2 5.8 ± 1.6 6.6 ± 2.6
r-Hcy, 𝜇mol/L 0.24 (0.15–0.37) 0.20 (0.13–0.37) 0.29 (0.18–0.37)
r-Cys, 𝜇mol/L 21.6 ± 4.1 20.9 ± 4.7 21.9 ± 3.5
r-GSH, 𝜇mol/L 1.09 (0.78–1.46) 1.01 (0.74–1.31) 1.11 (0.85–1.67)
r-Glu-Cys, 𝜇mol/L 0.36 (0.26–0.46) 0.35 (0.22–0.58) 0.37 (0.27–0.44)
Sum of reduced LMW thiols, 𝜇mol/L 29.4 ± 5.9 28.4 ± 5.9 30.5 ± 6.0
Thiols redox status
LMW redox, % 0.072 ± 0.027 0.066 ± 0.023 0.078 ± 0.030
PSH, 𝜇mol/g prot 3.95 (3.31–4.80) 3.59 (3.23–4.15) 4.61 (3.39–5.80)
common carotid arteries were averaged to calculate the mean
IMT. A thickness of >0.8mm indicated increased IMT.
2.5. Statistical Analysis. All results are expressed as mean
values (mean ± SD) ormedian values (median and interquar-
tile range). The variables distribution was assessed by the
Shapiro-Wilk test. Homogeneity of variance was checked
by 𝐹-test and differences between groups were compared
by nonparametric Mann-Whitney 𝑈 test or by parametric
independent 𝑡-test, with or without Welch’s correction for
unequal variances, as appropriate. Nonnormally distributed
variables were log 10-transformed prior assessment with
parametric tests, and the normal distribution of the residuals
was checked to assess the goodness of fit of the transforma-
tions. Correlation analysis between variables was performed
by Pearson’s correlation or Spearman’s correlation. Multiple
linear regression analysis was used to assess the association
between different variables and IMT at baseline. The effect of
treatment was evaluated by ANOVA.
Statistical analyses were performed using MedCalc for
Windows, 12.5 64-bit version (MedCalc Software, Ostend,
Belgium), and SPSS for Windows, 14.0 32-bit version (IBM
Corporation, Armonk, NY, USA).
3. Results
Clinical characteristics of CKD patients at baseline are
described in Table 1. After randomization, no significant
differences were found among the two treatment groups
in the clinical characteristics (Table 1). As expected, more
than 60% of CKD subjects were hyperhomocysteinemic (Hcy
>15 𝜇mol/L) versus 10% normally found in healthy popula-
tion. As reported in Figure 1, baseline IMT was inversely
related to PSH concentrations (𝑟 = −0.42, 𝑝 = 0.039). In
multiple linear regression analysis, with IMT as dependent
variable and age, gender, GFR, creatinine, PSH, SBP, and
LMW red/ox ratio as independent variables, only PSH (𝛽 =
−0.51,𝑝 = 0.027) was independently associated with baseline
IMT.
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Table 2: Drug effects on blood pressure and renal function markers.
Group 1 (𝑛 = 12) Group 2 (𝑛 = 12)
Baseline Telmisartan/ramipril40/5mg/day
𝑝 value
Baseline Telmisartan80mg/day
𝑝 value
Mean ± SD
or median (IQR)
Mean ± SD
or median (IQR)
Mean ± SD
or median
(IQR)
Mean ± SD
or median
(IQR)
Systolic BP, mmHg 132 ± 13 122 ± 10 0.04 133 ± 14 123 ± 15 0.11
Diastolic BP, mmHg 82 ± 8 75 ± 5 0.02 77 ± 9 76 ± 10 0.80
Creatinine, mg/dL 1.6 (1.0–2.3) 1.5 (1.1–2.2) 0.57 1.7 (1.3–2.0) 1.5 (1.3–2.0) 0.85
GFR, mL/min per 1.73m2 48 (22–71) 47 (23–61) 0.79 48 (34–66) 55 (36–71) 0.79
Proteinuria, g/24 h 0.52 (0.28–2.49) 0.49 (0.22–1.15) 0.07 1.28 (0.36–2.35) 0.67 (0.44–1.68) 0.08
0.1
1
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1 10
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Figure 1: Correlation between carotid IMT and PSH in CKD
patients at baseline.
As reported in Table 2, a reduction in blood pressure
was observed in both groups; however it was statistically
significant only in the telmisartan/ramipril group (𝑝 <
0.05). Creatinine and proteinuria showed a nonsignificant
trend toward improvement in both groups after 6-month
treatment. LMW thiols concentrations were unaffected by
drug treatment both in the reduced and in the total form.
In particular no differences were found in the cardiovascular
risk factors homocysteine and cysteine plasma concentra-
tions. As a result, the LMW red/ox ratio remained essentially
unchanged at the end of treatment (Table 3).
By contrast, as shown in Figure 2(a), PSH plasma con-
centrations significantly increased in the telmisartan/ramipril
group (median: 3.59 𝜇mol/g prot (3.31–4.80 𝜇mol/g prot) at
baseline versus 4.66 𝜇mol/g prot (3.94–5.96 𝜇mol/g prot)
after treatment,𝑝 = 0.015) whereas they remained essentially
unchanged in the telmisartan group (median: 4.61 𝜇mol/g
prot (3.39–5.80𝜇mol/g prot) at baseline versus 4.43 𝜇mol/g
prot (4.16–7.27𝜇mol/g prot) after treatment). Carotid IMT
decreased in both groups (Figure 2(b)). However, the
reduction was statistically significant only in the telmisar-
tan/ramipril group [telmisartan/ramipril: median 0.95mm
(0.72–1.05mm) at baseline versus 0.68mm (0.60–0.80mm)
after treatment, 𝑝 = 0.027; telmisartan: median 0.88mm
(0.73–1.00mm) at baseline versus 0.68mm (0.55–0.93) after
treatment].
4. Discussion
A number of trials and meta-analyses have demonstrated
that combined treatment with ACEIs and ARBs exerts
greater effects on blood pressure lowering and proteinuria
than agent alone [22, 23]. However, combination therapy
may also result in a significant increased incidence of
adverse effects, as demonstrated in the ONTARGET trial of
25,620 patients with preexisting vascular disease or diabetes.
ONTARGET was designed to evaluate the effects of ramipril,
telmisartan, or their combination on cardiovascular and
renal endpoints during approximately 4.5 years of follow-
up [24]. In this study, a small but significant increase in
the incidence of ESRD, hyperkalemia, and hypotension was
observed with the combination therapy [24]. Moreover,
the combination treatment was not associated with better
clinical outcomes when compared with each treatment alone
[25].
In view of the ongoing debate on the efficacy and safety
of combined RAS inhibitors treatment and the uncertainties
regarding the putative mechanisms responsible for the ben-
eficial effects of these drug class, we assessed and compared
the effects of telmisartan administration alone (80mg day)
versus a combination of telmisartan/ramipril (40/5mg day)
on plasma LMW and protein thiols concentrations and
carotid IMT in CKD patients. Our data confirm previous
observations that dual RAS blockade has greater blood
pressure effects if compared with telmisartan alone [24]. For
the first time, we comprehensively evaluated the effect of
RAS inhibitor therapy on low molecular mass thiols Hcy and
Cys (two well known risk factors for cardiovascular disease)
both in the total and in the reduced form. As expected, CKD
was associated with relatively high plasma concentrations of
both total Cys and Hcy. RAS treatment did not exert any
significant effect on plasma low molecular mass thiols (for
both reduced and total forms) so that LMW thiols redox
status remains unchanged after therapy. Conversely, com-
bined treatment significantly increased PSH concentrations.
PSH values provide a comprehensivemeasure of total protein
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Figure 2: Comparison between PSH levels (a) and IMT values (b) at baseline and after six months of therapy. ∗𝑝 < 0.05.
Table 3: Drug effects on LMW thiols.
Group 1 (𝑛 = 12) Group 2 (𝑛 = 12)
Baseline Telmisartan/ramipril40/5mg/day
p value
Baseline Telmisartan80mg/day
p valueMean ± SD
or
median (IQR)
Mean ± SD
or
median (IQR)
Mean ± SD
or
median (IQR)
Mean ± SD
or
median (IQR)
Total LMW thiols
t-CysGly, 𝜇mol/L 31.6 ± 8.8 31.1 ± 8.5 0.89 28.8 ± 8.4 25.6 ± 7.9 0.35
t-Hcy, 𝜇mol/L 16.3 (12.1–26.3) 17.3 (10.3–27.6) 0.90 19.2 (11.8–23.7) 14.4 (11.2–19.2) 0.27
t-Cys, 𝜇mol/L 391 ± 89 404 ± 122 0.77 370 ± 109 341 ± 94 0.49
t-GSH, 𝜇mol/L 7.4 ± 2.1 7.7 ± 1.8 0.71 7.6 ± 3.2 7.6 ± 4.6 1.00
t-GluCys, 𝜇mol/L 5.7 (4.5–6.0) 5.7 (4.4–9.7) 0.38 5.4 (3.5–7.6) 4.4 (3.2–7.2) 0.95
Sum of total LMW
thiols, 𝜇mol/L 458 ± 106 472 ± 144 0.79 432 ± 122 400 ± 112 0.51
Reduced LMW thiols
r-CysGly, 𝜇mol/L 5.8 ± 1.6 5.5 ± 1.6 0.65 6.6 ± 2.6 6.4 ± 1.7 0.83
r-Hcy, 𝜇mol/L 0.20 (0.13–0.37) 0.17 (0.12–0.36) 0.57 0.29 (0.18–0.37) 0.23 (0.17–0.29) 0.42
r-Cys, 𝜇mol/L 20.9 ± 4.7 19.7 ± 4.7 0.54 21.9 ± 3.5 21.0 ± 4.4 0.58
r-GSH, 𝜇mol/L 1.01 (0.74–1.31) 0.94 (0.47–1.37) 0.91 1.11 (0.85–1.67) 1.10 (0.71–1.60) 0.34
r-GluCys, 𝜇mol/L 0.35 (0.22–0.58) 0.41 (0.31–0.47) 0.85 0.37 (0.27–0.44) 0.43 (0.33–0.45) 0.97
Sum of reduced
sLMW thiols, 𝜇mol/L 28.4 ± 5.9 26.1 ± 5.1 0.32 30.5 ± 6.0 29.3 ± 5.8 0.62
Thiols redox status
LMW redox, % 0.066 ± 0.023 0.061 ± 0.025 0.62 0.078 ± 0.030 0.079 ± 0.028 0.93
sulfhydryl groups in plasma. The most abundant reduced -
SH group in plasma is that of human serum albumin (HSA),
given its high concentrations. The single free cysteinyl thiol
of HSA, Cys34, accounts for ∼80% of reduced thiols in
human plasma and is an important scavenger of reactive
oxygen and nitrogen species in the vascular compartment,
thus a quantitatively important redox buffer of blood [26].
Therefore, in the presence of reactive oxygen species the
PSH concentrations decrease, whereas an increment in PSH
concentrations indicates oxidative stress reduction. Our data
on PSH are in agreement with previous reports showing
that ramipril effectively decreased oxidative stress indices
[17].
Notably, the salutary effects of RAS combination treat-
ment were paralleled by a concomitant reduction in carotid
IMT. As baseline PSH was the only parameter independently
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associated with IMT, we speculate that the changes in IMT
during combination treatment may be mediated, at least in
part, by the reduction of oxidative stress. This hypothesis
is supported by previous studies showing an inverse asso-
ciation between IMT and plasma total antioxidant capacity
[27].
There are some limitations in this study that deserve
mention.The data were obtained from a relatively small study
population and did not include a placebo group. Therefore,
our results require confirmation in larger study cohorts. The
treatment duration, 6 months, is relatively short if compared
to previous studies, reporting follow-ups between 2 and 4
years. Finally, the applicability of our results to populations
other than CKD remains to be established, in view of the
peculiar proinflammatory and oxidative stress state of these
patients.
5. Conclusion
We found that 6-month RAS inhibitor treatment in CKD
with either telmisartan alone or in combination with ramipril
did not significantly affect LMW plasma thiols in both the
reduced and the total form, particularlyHcy andCys. By con-
trast, a significant reduction in carotid IMT and a concomi-
tant increase in PSH plasma concentrations were observed
in the combination treatment group. These results provide
novel information on the potential mechanistic effects of
RAS inhibition on carotid IMT, a key marker of vascular
remodeling and independent predictor of adverse events in
hypertension and CKD. Further studies in larger cohorts
with longer follow-ups and other established surrogate risk
markers are required to confirm the hypothesis that the IMT
improvement with RAS inhibition is mediated by oxidative
stress decrease.
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